Studying test results to predict and diagnose melanoma
Part of Cancer, Genetic & congenital, Skin clinical trials.
This study looks at diagnostic and prognostic factors in people who have suspicious pigmented skin lesions or melanoma that doctors are evaluating with surgery or tissue sampling. It may help improve how clinicians decide what the lesion is and what to expect over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are followed in routine dermatology, surgery, or oncology care in Helsingborg, Lund, Malmö, or Kristianstad hospitals.
- You have a suspicious pigmented skin spot planned for surgical removal (or you have metastatic melanoma planned for surgery or needle sampling).
- Your doctors think the spot could be melanoma, or a different condition that looks similar.
- You can sign a written informed consent form to join the study.
- Your lesion(s) must be large enough that taking a small sample for the study would not interfere with the usual diagnosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the DNA and other biology from skin lesions (like melanoma or unusual pigmented moles) in children and teens. It aims to better understand what these tumors are and how they behave, using tissue samples collected during routine care.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study looks at serial (repeated) tumour biopsies and blood samples in people with advanced melanoma. The goal is to understand biomarkers and disease changes over time, which may help improve future treatment decisions.
This study looks at your melanoma's gene activity and a blood test for tumor DNA to help predict the risk of the cancer coming back. You will need to provide blood and tissue samples, and the goal is to find better ways to personalize treatment for people with thicker, high-risk melanomas.
This study looks at people and families with a high risk of melanoma, especially if it runs in the family or is linked to certain genetic conditions. The goal is to better understand what causes melanoma and how to detect it earlier.
This trial is looking at a protein called CD160 on immune cells (NK cells) in melanoma patients. The goal is to understand if this protein can be a target for new treatments. By studying your blood and tumor samples, researchers hope to find better ways to treat advanced melanoma.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.